[Edaily] Moon-Tae Yoon, CEO of C&R Research, collaborates with Kakao on CDISC clinical standardization… ‘Crossing the FDA Threshold’
C&R Research, a contract research organization (CRO) is undergoing a complete overhaul of its clinical data collection method. They are transitioning to the internationally standardized method designated by the Clinical Data Interchange Standards Consortium (CDISC).
Moon-Tae Yoon, CEO of C&R Research, emphasized in an interview with Edaily on the 8th, “Korea should quickly legislate the adoption of the CDISC method when conducting new drug trials.” While the United States, Europe, Japan, and China all collect clinical data and accumulate big data using this method, the methods for collecting clinical data in Korea vary. According to CEO Moon-Tae Yoon, this means that submitting data to the U.S. Food and Drug Administration (FDA) would also require a new data conversion process.
